CAB-AXL-ADC for Melanoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Melanoma+11 MoreCAB-AXL-ADC - Biological
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Melanoma
  • Bone Sarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Osteosarcoma
  • Ewing Sarcoma
  • Synovial Sarcoma
  • Soft Tissue Sarcoma
  • Sarcoma
  • Refractory Sarcoma
  • Solid Tumors
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

7 Primary · 13 Secondary · Reporting Duration: Up to 24 months

Week 3
Dose Limiting Toxicities (DLTs)
Up to 24 months
Anti-tumor activity
Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3011)
Immunogenicity of BA3011
Pharmacokinetics: AUC
Pharmacokinetics: Cmax
Phase 1 and 2: Best overall response (OR)
Phase 1 and 2: Disease control rate (DCR)
Phase 1 and 2: Duration of response (DOR)
Phase 1 and 2: Overall survival (OS)
Phase 1 and 2: Progression-free survival (PFS)
Phase 1 and 2: Safety Profile
Phase 1 and 2: Time to response (TTR)
Phase 1 and 2: Tumor size
Phase 1: Immunogenicity
Phase 1: Overall response rate (ORR)
Phase 1: Pharmacokinetics
Phase 1: Safety Profile
Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1
Week 3
Maximum Tolerated Dose (MTD)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

BA3011
1 of 2
Combination Therapy
1 of 2

Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: CAB-AXL-ADC · No Placebo Group · Phase 1 & 2

BA3011
Biological
Experimental Group · 1 Intervention: CAB-AXL-ADC · Intervention Types: Biological
Combination TherapyExperimental Group · 2 Interventions: CAB-AXL-ADC, PD-1 inhibitor · Intervention Types: Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PD-1 inhibitor
2019
Completed Phase 2
~580

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

BioAtla, Inc.Lead Sponsor
5 Previous Clinical Trials
796 Total Patients Enrolled
2 Trials studying Melanoma
456 Patients Enrolled for Melanoma

Eligibility Criteria

Age Any Age · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: